Bio Genuine (Shanghai) Biotech Co., Ltd.
Quick facts
Phase 3 pipeline
- Add-back therapy · Gynecology / Endometriosis / Uterine Fibroids
Add-back therapy restores hormonal levels that were suppressed by prior treatment, typically used to mitigate side effects of GnRH agonists in endometriosis or uterine fibroids. - BG2109 · Diabetes
BG2109 is a small molecule drug that targets the SGLT2 receptor. - Placebo for add-back therapy · Endocrinology
This drug serves as a placebo for add-back therapy. - Placebo for BG2109
A placebo control has no active pharmacological mechanism.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: